La Vie Health and Virotek Biosciences Partner to Advance the Next Generation of Precision Health
Ontario and Richmond Hill, Ontario--(Newsfile Corp. - September 15, 2026) - La Vie Health ("La Vie") and Virotek Biosciences ("Virotek") today announced a strategic collaboration to integrate advanced genomic insights into La Vie's broader physician-led preventative, precision and healthspan model. This partnership advances both companies' commitment to precision health, with Virotek adding a clinically contextualized genomic layer to La Vie's comprehensive precision-health prog
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-15 8:30 AM EDT | Virotek Biosciences Inc.
Adia Med Submits Fifth 2026 Clinical Study to IRB: Osteoarthritis Protocol for One-Time Systemic Treatment
Winter Park, Florida--(Newsfile Corp. - September 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted a clinical study protocol to an Institutional Review Board for review and approval. The proposed study is designed to evaluate a one-time systemic treatment with AdiaVita, the Company's umbilical cord blood-derived stem cell and exosome product, in adults with osteoarthritis. Participa
Healthcare and Hospitals, Health
2026-09-15 8:00 AM EDT | Adia Med Inc.
Extendicare Announces September 2026 Dividend of C$0.0441 per Share
Markham, Ontario--(Newsfile Corp. - September 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of September 2026, which is payable on October 15, 2026 to shareholders of record at the close of business on September 30, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare
Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-15 8:00 AM EDT | Extendicare Inc.
CareRx Receives Regulatory Approval for Renewal of its Normal Course Issuer Bid
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today announced that the Toronto Stock Exchange ("TSX") has accepted its notice to make a normal course issuer bid to repurchase outstanding common shares in the capital of the Corporation ("Common Shares"). "The renewal of our share
2026-09-15 7:30 AM EDT | CareRx Corporation
Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Good Laboratory Practice ("GLP") toxicology analysis of intravenously administered Ru
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-09-15 7:00 AM EDT | Theralase Technologies Inc.
HEALWELL's DARWEN(TM) AI Outperforms Published Foundation Model Benchmarks and Demonstrates Real-World Patient Impact in New Peer-Reviewed Research
New research accepted for presentation at AMIA 2026 demonstrates the performance of HEALWELL's DARWEN™ AI-powered SMARTSuite, including clinical summarization results that outperformed published benchmarks for OpenAI's GPT, DeepSeek and Llama across all three measures used to evaluate clinical summarization accuracy. Separate DARWEN™ AI validation research accepted for oral presentation at AI-MEDX 2026 demonstrated nearly 50% higher treatment-plan accuracy t
Technology, Healthcare and Hospitals
2026-09-15 6:00 AM EDT | HEALWELL AI
medmix Secures Second Consecutive CDP "A" Rating for Supplier Engagement
Baar, Switzerland--(Newsfile Corp. - September 15, 2026) - medmix has secured an "A" rating in CDP's Supplier Engagement Assessment for the second consecutive year, placing the company among a select group of global leaders recognized for driving climate action across their supply chains. CDP's Supplier Engagement Assessment
Technology, Construction / Building, Healthcare and Hospitals, Household / Consumer / Cosmetics
2026-09-15 3:06 AM EDT | medmix AG
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that, following the formal completion of the Phase 1b clinical study, it has submitted a meeting request and comprehensive briefing package to the U.S. Food and Drug Administration (FDA).
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-14 7:00 AM EDT | Phio Pharmaceuticals Corp.
Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.
Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Steven Sangha announces he has entered into a voting and support agreement ("Voting Agreement") with Seraxis Holdings, Inc. ("Seraxis") in connection with Seraxis's proposal ("Proposed Transaction") to acquire all of the securities of Sernova Biotherapeutics Inc. ("Sernova") pursuant to an arrangement agreement dated September 7, 2026 between Seraxis and Sernova ("Arrangement Agreement"). Pursuant to the Arrangement Agreement, h
2026-09-11 5:40 PM EDT | Dr. Steven S. Sangha
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte Ne
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-11 9:00 AM EDT | Phio Pharmaceuticals Corp.
Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's Prevention of Heart Failure
Calgary, Alberta--(Newsfile Corp. - September 10, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the publication of two new scientific journal articles on mechanisms relating to heart failure prevention by the Company's lead clinical candidate, apabetalone. "One of the most striking findings from BETonMACE was the reduction in heart failure hospitalizations among apabetalone-treated patients," said Dr. Ewelina Kulikowski, PhD, Chief Scien
Technology, Biotechnology, Healthcare and Hospitals
2026-09-10 7:15 AM EDT | Resverlogix Corp.
medmix' Drug Delivery ("Haselmeier") to Support the Development of Xeris Pharmaceuticals' XP-8121 with D-Flex(TM) Pen Injector
Baar, Switzerland--(Newsfile Corp. - September 10, 2026) - medmix’ Drug Delivery (“Haselmeier”) announces its collaboration with Xeris Pharmaceuticals to support the development of Xeris’ XP-8121 product candidate, an investigational once-weekly subcutaneous levothyroxine therapy in development for the treatment of hypoth
Technology, Construction / Building, Healthcare and Hospitals, Household / Consumer / Cosmetics
2026-09-10 3:06 AM EDT | medmix AG
MD Hyperbaric Appoints Renowned Hyperbaric Researcher Dr. Amir Hadanny as Chief Medical Officer
New York, New York--(Newsfile Corp. - September 9, 2026) - MD Hyperbaric, one of the fastest-growing hyperbaric oxygen therapy (HBOT) networks in the United States, announced the appointment of Amir Hadanny, MD, as Chief Medical Officer. Dr. Hadanny is a neurosurgeon and hyperbaric physician and one of the most published clinical researchers in hyperbaric medicine, with more than 80 peer-reviewed publications. In this role,
Healthcare and Hospitals, Health
2026-09-09 9:00 AM EDT | MD Hyperbaric
LevelJump Announces Management Change
Toronto, Ontario--(Newsfile Corp. - September 9, 2026) - LevelJump Healthcare Corp. - (TSXV: JUMP) ("LevelJump" or the "Company") wishes to announce the appointment of Gus Patel as the Company's interim Chief Financial Officer effective September 1, 2026, replacing Robert Landau. Gus Patel is a finance executive, tax practitioner and licensed public accountant with more than 15 years of experience across public companies, private enterprises and professiona
Healthcare and Hospitals, Health
2026-09-09 8:37 AM EDT | LevelJump Healthcare Corp.
MODUS Structures Acquires ROC Modular, Creating One of Canada's Largest Modular Construction Companies
Crossfield, Alberta--(Newsfile Corp. - September 9, 2026) - MODUS Structures Inc. ("MODUS") today announced that it has completed the acquisition of ROC Modular Inc. ("ROC"), bringing together two established Canadian modular construction businesses. The combined company will operate under the MODUS Structures brand and, based on its workforce, manufacturing footprint and breadth of capabilities, will be one of the largest modular construction companies in Canada. The combination create
Construction / Building, Healthcare and Hospitals, Housing, Aboriginal / Indigenous
2026-09-09 7:00 AM EDT | Modus Structures Inc
WELL Health Announces Planned CFO Transition; Evelyn Sutherland Appointed Chief Financial Officer
WELL has appointed Evelyn Sutherland as Chief Financial Officer, effective September 21, 2026. Ms. Sutherland brings more than 20 years of senior financial leadership experience, including CFO roles at Staples Canada, Enercare Inc., KEYreit, and United Purchasing Group of Canada (Yum! Brands). Ms. Sutherland has served on the Board of WELL's subsidiary, WELLSTAR, over the past year and brings direct knowledge of the Company's strategy, governance an
Technology, Computer Software, Healthcare and Hospitals, Health
2026-09-09 6:00 AM EDT | WELL Health Technologies Corp.
Discovery Senior Living to Participate in Evercore ISI Healthcare Investment Conference
Bonita Springs, Florida--(Newsfile Corp. - September 8, 2026) - Discovery Senior Living ("Discovery" or "DSL"), one of the one of the largest and most trusted senior housing operators in the U.S., is pleased to announce that Chief Executive Officer Richard Hutchinson will participate in the Evercore ISI Virtual REIT Conference on Wednesday, September 9, 2026.
Healthcare and Hospitals, Real Estate, Housing
2026-09-08 11:33 AM EDT | Discovery Senior Living
Nasdaq Shareholder Requirements Just Verified By Adia Med
Winter Park, Florida--(Newsfile Corp. - September 8, 2026) - Nasdaq requires companies seeking an initial listing on the Nasdaq Capital Market to have a sufficiently broad public shareholder base. That distribution test includes: At least 300 round-lot holders; A round-lot holder generally meaning a shareholder holding at least 100 unrestricted shares; and Adia Med has just verified that it currently has 361 round-lot holders, or
Healthcare and Hospitals, Health
2026-09-08 8:00 AM EDT | Adia Med Inc.
WELL Health Announces WELLTRUST(TM) Surpasses 100,000 Patient Consents
WELLTRUST™, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. HEALWELL's DARWEN™ AI platform is used to connect WELLTRUST™ patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Orga
Technology, Computer Software, Healthcare and Hospitals, Health
2026-09-08 6:30 AM EDT | WELL Health Technologies Corp.
HEALWELL's DARWEN(TM) to Power AI-Driven Clinical Trial Matching for WELLTRUST(TM), a Network of Over 100,000 Consented Patients
HEALWELL's DARWEN™ AI platform is used to connect WELLTRUST™ patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Organizations (CROs), by matching trial protocols against the consented patient population. WELLTRUST™, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be cont
Technology, Healthcare and Hospitals
2026-09-08 6:30 AM EDT | HEALWELL AI